AR079552A1 - Metodo para el tratamiento de la fibrilacion atrial. formulacion farmaceutica - Google Patents

Metodo para el tratamiento de la fibrilacion atrial. formulacion farmaceutica

Info

Publication number
AR079552A1
AR079552A1 ARP100104774A ARP100104774A AR079552A1 AR 079552 A1 AR079552 A1 AR 079552A1 AR P100104774 A ARP100104774 A AR P100104774A AR P100104774 A ARP100104774 A AR P100104774A AR 079552 A1 AR079552 A1 AR 079552A1
Authority
AR
Argentina
Prior art keywords
treatment
atrial
pharmaceutical formulation
atrial fibrilation
pharmaceutically acceptable
Prior art date
Application number
ARP100104774A
Other languages
English (en)
Spanish (es)
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43736345&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR079552(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of AR079552A1 publication Critical patent/AR079552A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP100104774A 2009-12-21 2010-12-20 Metodo para el tratamiento de la fibrilacion atrial. formulacion farmaceutica AR079552A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28873909P 2009-12-21 2009-12-21

Publications (1)

Publication Number Publication Date
AR079552A1 true AR079552A1 (es) 2012-02-01

Family

ID=43736345

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100104774A AR079552A1 (es) 2009-12-21 2010-12-20 Metodo para el tratamiento de la fibrilacion atrial. formulacion farmaceutica

Country Status (37)

Country Link
US (3) US8513254B2 (ja)
EP (2) EP2515900B1 (ja)
JP (2) JP5723889B2 (ja)
KR (2) KR20120107995A (ja)
CN (3) CN102665713B (ja)
AP (1) AP3536A (ja)
AR (1) AR079552A1 (ja)
AU (1) AU2010339753B2 (ja)
BR (1) BR112012015499A2 (ja)
CA (1) CA2784028C (ja)
CL (1) CL2012001597A1 (ja)
CR (1) CR20120353A (ja)
CY (1) CY1116511T1 (ja)
DK (1) DK2515900T3 (ja)
EA (2) EA025445B1 (ja)
EC (1) ECSP12012004A (ja)
ES (2) ES2540093T3 (ja)
HK (1) HK1170675A1 (ja)
HR (1) HRP20150644T1 (ja)
HU (1) HUE026916T2 (ja)
IL (1) IL220152A (ja)
ME (1) ME02179B (ja)
MX (2) MX344329B (ja)
NO (1) NO2749282T3 (ja)
NZ (2) NZ600718A (ja)
PE (1) PE20121520A1 (ja)
PL (2) PL2749282T3 (ja)
PT (2) PT2749282T (ja)
RS (1) RS54118B1 (ja)
SG (3) SG10201710751TA (ja)
SI (2) SI2749282T1 (ja)
SM (1) SMT201500171B (ja)
TW (1) TWI508726B (ja)
UA (1) UA109887C2 (ja)
UY (1) UY33119A (ja)
WO (1) WO2011084733A1 (ja)
ZA (1) ZA201204608B (ja)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0311161A (pt) 2002-05-21 2005-03-29 Cv Therapeutics Inc Método de tratamento de diabetes
DK2464645T3 (en) 2009-07-27 2017-10-23 Gilead Sciences Inc CONDENSED, HETEROCYCLIC COMPOUNDS AS IRON CHANNEL MODULATORS
JP5829608B2 (ja) 2009-07-29 2015-12-09 アイシーユー・メディカル・インコーポレーテッド 流体移行デバイスおよびその使用方法
WO2011135582A2 (en) * 2010-04-28 2011-11-03 Cadila Healthcare Limited Pharmaceutical compositions of dronedarone
CN103096977B (zh) 2010-07-02 2017-02-15 吉利德科学公司 作为离子通道调节剂的稠杂环化合物
WO2012154760A1 (en) 2011-05-10 2012-11-15 Gilead Sciences, Inc. Fused heterocyclic compounds as sodium channel modulators
TWI549944B (zh) 2011-07-01 2016-09-21 吉李德科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
NO3175985T3 (ja) 2011-07-01 2018-04-28
JP2015504923A (ja) * 2012-01-27 2015-02-16 ギリアード サイエンシーズ， インコーポレイテッド 後期ナトリウムイオンチャネル遮断剤およびカリウムイオンチャネル遮断剤を使用する併用療法
WO2014179764A1 (en) * 2013-05-03 2014-11-06 Gilead Sciences, Inc. Method of treating atrial fibrillation
AU2014296378B2 (en) * 2013-08-02 2017-03-30 Gilead Sciences, Inc. Pharmaceutical compositions of ranolazine and dronedarone
WO2015073922A2 (en) 2013-11-15 2015-05-21 Northwestern University Inhibition of oxidative stress in atrial fibrillation
KR101918375B1 (ko) 2013-12-19 2018-11-13 길리애드 사이언시즈, 인코포레이티드 이온 채널 조정제로서의 융합된 헤테로시클릭 화합물
CN104951870B (zh) * 2015-06-01 2018-11-13 南通科瑞斯生物医药科技有限公司 药物临床前心脏风险评估方法
US20190119236A1 (en) 2016-02-23 2019-04-25 Portola Pharmaceuticals, Inc. Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9)
AU2017228371A1 (en) 2016-03-04 2018-09-13 Gilead Sciences, Inc. Compositions and combinations of autotaxin inhibitors
US10575744B2 (en) 2017-02-24 2020-03-03 Medtronic Cryocath Lp Pericardial balloon mapping
US10799703B2 (en) * 2017-12-22 2020-10-13 Medtronic, Inc. Evaluation of his bundle pacing therapy
EP3530182B1 (en) * 2018-02-27 2020-12-09 Nokia Technologies Oy Apparatus and method for determining a change in left ventricular twist of a subject's heart
EP3914709A4 (en) * 2019-01-24 2023-05-03 Northwestern University GENE THERAPY TREATMENT OF ATRIAL FIBRILLATION

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4567264A (en) 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
ATE223218T1 (de) 1989-06-23 2002-09-15 Syntex Llc Ranolazin und verwandte piperazine zum schutz der skelettmuskulatur
FR2665444B1 (fr) 1990-08-06 1992-11-27 Sanofi Sa Derives d'amino-benzofuranne, benzothiophene ou indole, leur procede de preparation ainsi que les compositions les contenant.
US5455045A (en) 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
ZA953078B (en) 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
FR2764800B1 (fr) 1997-06-23 1999-09-10 Sanofi Sa Composition pharmaceutique solide contenant des derives de benzofuranne
US6303607B1 (en) 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
JP2004505061A (ja) 2000-07-27 2004-02-19 ファルマシア・コーポレーション うっ血性心不全の処置のための、エポキシ−ステロイド型アルドステロン拮抗薬とカルシウムチャンネル遮断薬の併用療法
FR2817750B1 (fr) 2000-12-11 2003-02-21 Sanofi Synthelabo Composition pharmaceutique de dronedarone pour administration parenterale
DE60117857D1 (de) 2000-12-27 2006-05-04 Genzyme Corp Kontrollierte freisetzung von anti-arrhythmica aus einem biodegradierbaren hydrogel für die lokale anwendung am herzen
EP1408958A1 (en) 2001-07-20 2004-04-21 Karo Bio Ab Benzofuranes and their use in the treatment of atrial fibrillation
US20060003002A1 (en) * 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
US7772232B2 (en) 2004-04-15 2010-08-10 Bristol-Myers Squibb Company Quinazolinyl compounds as inhibitors of potassium channel function
JP2008526879A (ja) 2005-01-06 2008-07-24 シーブイ・セラピューティクス・インコーポレイテッド ラノラジンを含有する徐放性薬学的処方物
WO2007053610A2 (en) 2005-11-01 2007-05-10 The Regents Of The University Of California Methods of treating atrial fibrillation wtih pirfenidone
CA2678272A1 (en) 2007-02-13 2008-10-02 Cv Therapeutics, Inc. Use of ranolazine for the treatment of cardiovascular diseases
US20090247535A1 (en) 2008-03-26 2009-10-01 Duke University Use of ranolazine for non-cardiovascular disorders
EP2133074A1 (en) * 2008-06-10 2009-12-16 Sanofi-Aventis Use of dronedarone for the preparation of a medicament intended for the prevention of permanent atrial fibrillation
WO2010028173A2 (en) 2008-09-04 2010-03-11 Gilead Palo Alto, Inc. Method of treating atrial fibrillation

Also Published As

Publication number Publication date
SI2515900T1 (sl) 2015-07-31
CA2784028A1 (en) 2011-07-14
PL2749282T3 (pl) 2018-01-31
EP2515900B1 (en) 2015-04-29
CA2784028C (en) 2016-08-23
JP2013515007A (ja) 2013-05-02
JP2015057449A (ja) 2015-03-26
KR20160108611A (ko) 2016-09-19
ZA201204608B (en) 2013-02-27
ECSP12012004A (es) 2012-08-31
EA201691336A1 (ru) 2017-05-31
IL220152A0 (en) 2012-07-31
CY1116511T1 (el) 2017-03-15
TWI508726B (zh) 2015-11-21
DK2515900T3 (en) 2015-07-27
AP2012006331A0 (en) 2012-06-30
AP3536A (en) 2016-01-13
MX344329B (es) 2016-12-13
CR20120353A (es) 2014-10-07
PL2515900T3 (pl) 2015-10-30
EA025445B1 (ru) 2016-12-30
WO2011084733A1 (en) 2011-07-14
BR112012015499A2 (pt) 2016-05-03
HK1170675A1 (en) 2013-03-08
CN104688739A (zh) 2015-06-10
ME02179B (me) 2015-10-20
US20140323493A1 (en) 2014-10-30
HRP20150644T1 (hr) 2015-07-31
EP2749282A1 (en) 2014-07-02
PT2515900E (pt) 2015-07-30
KR20120107995A (ko) 2012-10-04
ES2540093T3 (es) 2015-07-08
SG181541A1 (en) 2012-07-30
HUE026916T2 (en) 2016-08-29
TW201136586A (en) 2011-11-01
US9056108B2 (en) 2015-06-16
US8754087B2 (en) 2014-06-17
UA109887C2 (uk) 2015-10-26
SG10201408528RA (en) 2015-04-29
AU2010339753B2 (en) 2015-01-22
US20130317038A1 (en) 2013-11-28
SI2749282T1 (sl) 2017-12-29
AU2010339753A1 (en) 2012-07-12
US20110183990A1 (en) 2011-07-28
NZ627181A (en) 2016-02-26
EP2749282B1 (en) 2017-08-09
US8513254B2 (en) 2013-08-20
CN102665713A (zh) 2012-09-12
PT2749282T (pt) 2017-11-15
CN104147010A (zh) 2014-11-19
SMT201500171B (it) 2015-09-07
PE20121520A1 (es) 2012-11-26
JP5723889B2 (ja) 2015-05-27
UY33119A (es) 2011-07-29
CL2012001597A1 (es) 2013-06-28
IL220152A (en) 2016-11-30
ES2646603T3 (es) 2017-12-14
MX2012007052A (es) 2012-07-30
RS54118B1 (en) 2015-12-31
CN102665713B (zh) 2015-02-18
NZ600718A (en) 2014-08-29
NO2749282T3 (ja) 2018-01-06
SG10201710751TA (en) 2018-02-27
EA201290451A1 (ru) 2013-01-30
EP2515900A1 (en) 2012-10-31

Similar Documents

Publication Publication Date Title
AR079552A1 (es) Metodo para el tratamiento de la fibrilacion atrial. formulacion farmaceutica
CO2019015090A2 (es) Métodos de tratamiento para la fibrosis cística
MX2020010484A (es) Derivados de heterociclilos sustituidos como inhibidores de cdk.
CY1119007T1 (el) Συνθεσεις και μεθοδοι αγωγης πνευμονικης υπερτασης
PH12016501750A1 (en) Human plasma kallikrein inhibitors
ECSP12012002A (es) Compuesto heterocíclico conteniendo nitrógeno y fungicida para el uso en agricultura y jardinería
MX2021004639A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
WO2010028173A3 (en) Method of treating atrial fibrillation
BR112015006828A2 (pt) composto, ou um sal farmaceuticamente aceitável do mesmo; composição farmacêutica; método para tratar uma doença em um paciente em necessidade do tratamento; e método para modular a atividade de uma proteína ire1
AR074313A1 (es) Metodo para tratar o prevenir la trombosis utilizando etexilato de dabigatran o una sal del mismo. uso. kit
PE20150161A1 (es) Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
CL2011000806A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular.
ECSP13012847A (es) Dimaleato de 9-[4-(3-cloro-2-fluoro-fenilamino)-7-metoxi-quinazolin-6-iloxi]-1,4-diaza-espiro[5.5]undecan-5-ona, su uso como medicamento y su preparación.
MX2021010297A (es) Inhibidores de calicreina plasmatica humana.
AR075179A1 (es) Formulaciones galenicas de compuestos organicos que comprenden alisquireno
MX2016016400A (es) Formulaciones de oximetazolina estabilizadas y sus usos.
AR099299A1 (es) Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares
EA201270747A1 (ru) Композиции и способы для профилактики и лечения ран
AR072954A1 (es) Utilizacion de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatinina debido a la administracion de dronedarona, producto de fabricacion y envase
WO2016122288A3 (ko) 베르베논 유도체 및 재관류 치료제를 포함하는 뇌혈관 질환, 동맥경화증 또는 심혈관 질환 치료 또는 예방용 병용 제제
WO2015183985A3 (en) Therapeutic compositions including naphthoquinones and uses thereof
AR104427A1 (es) Composiciones farmacéuticas para terapia de combinación
UY37822A (es) Derivados del indol y sus usos

Legal Events

Date Code Title Description
FB Suspension of granting procedure